MetaCap

Propanc Biopharma (PPCB) vs PRF Technologies (PRFX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Propanc Biopharma is the larger company by market cap ($1.9 million vs $1.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PPCB+256.93%PRFX-45.79%
+409%+171%-67%
Oct 7, 20261 yearNov 20, 2026
PPCB+266.48%PRFX-45.86%
+317%+127%-63%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PPCB versus PRFX key metrics
MetricPPCBPRFX
Share price$1.78$0.4758
Market cap$1.87M$1.66M
1-day change+3.19%-23.68%
EPS (TTM)$-95.92$-4.09
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$17.00K
Net income (latest FY)$-18.86M$-5.02M
Gross margin—-311.76%
Operating margin—-30129.41%
Net margin—-29541.18%
52-week high$315.00$7.95
52-week low$1.61$0.46
Distance from 52-week high-99.43%-94.02%
Average volume188.66K228.55K
Shares outstanding1.05M3.50M
Employees26
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Propanc Biopharma

PPCB stock →

Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

About PRF Technologies

PRFX stock →

PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

PPCB vs PRFX FAQ

Which is bigger, Propanc Biopharma or PRF Technologies?

Propanc Biopharma (PPCB) is larger, with a market capitalization of $1.87M compared with $1.66M for PRF Technologies (PRFX).

Are Propanc Biopharma and PRF Technologies in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons